A Cohort Study Evaluating the Efficacy of PO Magnesium in the Treatment of Acute Traumatic Brain Injury in Adolescents

• Status: Completed
• Trial end date: 2019-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the efficacy of magnesium in symptomatic reduction of mild traumatic brain injury in the adolescent population in the acute setting of injury.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Lakeland Health; Spectrum Health - Lakeland
• Collaborator: Michigan State University
• Treatments: Acetaminophen; Magnesium Oxide; Ondansetron

Criteria

Inclusion Criteria:

• • Age 12 to 18 years

• • Presenting chief complaint of headache, head injury, or concussion within the first 48 hours of injury.

• • GCS > 13 on arrival.

Exclusion Criteria:

• • Age < 12 years or > 18 years

• • Inability to provide informed consent

• • Vomiting > 2 episodes following injury

• • Physical or mental disability hindering adequate response to assessment of symptoms

• • Hemodynamic instability/medical condition requiring further acute life-saving medical intervention

• • Known brain mass, intracranial hemorrhage, skull fracture

• • Known contraindications to magnesium use

• • Known contraindication to Zofran use